Similar Search Results

Market Size in Innovation : Theory and Evidence from the Pharmaceutical Industry

Acemoglu, Daron; Linn, Joshua - 2015

This paper investigates the effect of (potential) market size on entry of new drugs and pharmaceutical innovation. Focusing on exogenous changes driven by U.S. demographic trends, we find that a 1 percent increase in the potential market size for a drug category leads to a 4 to 6 percent...

Persistent link: https://www.econbiz.de/10014075002

The impact of R&D cooperations on drug variety offered on the market : evidence from the pharmaceutical industry

Banerjee, Tannista; Siebert, Ralph - 2014

Our study puts special attention to the fact that R&D cooperations in the pharmaceutical industry are formed at different stages throughout the drug development process. We study if the timing to engage in R&D cooperations in the pharmaceutical industry has different impacts on the technology...

Persistent link: https://www.econbiz.de/10010229875

Product Innovation in a Model of Settlements of Drug Patent Litigation

Woodcock, Ramsi - 2017

A generic drug maker that has been sued for infringing a patent on a branded drug will sometimes promise, as part of an agreement settling the litigation, to delay selling its drug until as late as the expiration of the patent term. I adapt the standard optimal patent term model to determine...

Persistent link: https://www.econbiz.de/10014131063

Arzneimittelversorgung und -produktion gefährdet : AMNOG-Reform auf dem Prüfstand

Kirchhoff, Jasmina - 2022

Erstattungsbetragsverhandlungen innovativer Arzneimittel werden als Gefahr für die zukünftige Versorgung der Patienten und für den Forschungs- und … zweckmäßigen Vergleichstherapie gleichwertige Arzneimittel schlechter gestellt werden. Zum anderen können nur noch … Arzneimittel beeinflusst darüber hinaus die Standortentscheidungen pharmazeutischer Unternehmen. …

Persistent link: https://www.econbiz.de/10013468282

Research Exemption and Pharmaceutical Innovation : Evidence from China

Shi, C. Matthew; Zhao, Yucong - 2021

The patent laws of many countries have ''research exemption'' provisions that exempt certain research-related uses of proprietary materials from patent infringement. By limiting the rights of existing patent holders, such rules are meant to facilitate follow-on innovation and benefit latecomer...

Persistent link: https://www.econbiz.de/10013241201

Does In-House R&D Increase Bargaining Power? Evidence from the Pharmaceutical Industry

Arora, Ashish; Vogt, William B.; Yoon, Ji Woong - 2014

According to Gans & Stern (1999), firms engage in R&D spending, in part, in order to improve their bargaining position as buyers in the market for technology. We test this theory empirically with data from the pharmaceutical industry. We develop and estimate a structural model of R&D spending...

Persistent link: https://www.econbiz.de/10014028306

Is Europe a Laggard in Pharmaceuticals? R&D Joint Ventures, Patent Quality and R&D Productivity

Messinis, George - 2009

This paper examines the idea that the USA has outshined Europe in the race for new medicines as a result of a flight of business R&D expenditure to the USA. It adopts a methodology that accounts for R&D price inflation, considers the role of both ‘performed' R&D and ‘extra-mural' R&D, and...

Persistent link: https://www.econbiz.de/10013155663

Patent Quality and R&D Productivity in Pharmaceuticals : The Role of Inflation and International Collaboration

Messinis, George - 2009

supportive evidence for pharmaceuticals. This study revisits this hypothesis using OECD data for the period 1980-2000. It extends …

Persistent link: https://www.econbiz.de/10013155664

The development of firm size and innovativeness in the pharmaceutical industry between 1989 and 2010

Backfisch, Martin - 2018 - Version: 14 April 2018

Within the last decades, there have been many technological and regulatory changes in the pharmaceutical industry. Some of these developments facilitate the innovative activities of large firms, while others foster small firms. It is therefore surprising that the implications of these changes in...

Persistent link: https://www.econbiz.de/10011844257

The Impact of R&D Cooperations and Mergers in Pharmaceuticals on Research Activities and Drugs Offered on the Market

Banerjee, Tannista - 2017

In the last ten years, the pharmaceutical industry has experienced steep, unprecedented price increases. Pharmaceutical companies engage in R&D cooperations to cope with rocketing research and development (R&D) expenses.We study the impact of R&D cooperations on firms' research activities and...

Persistent link: https://www.econbiz.de/10012951300